A Phase 1/2 interventional study of VS-6063 and Paclitaxel in Ovarian Cancer, sponsored by Michael McHale. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-31.
Sponsored by Michael McHale · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,780 studies in Ovarian Neoplasms with a site in United States — 276 open to participants now, 452 under way, 46 of them phase 3. Ovarian Neoplasms · United States.
Among the 1,780 studies in Ovarian Neoplasms with a site in United States, this one is the 1,344th largest by enrollment of the 1,499 interventional ones that give a count, is one of 76 that started in 2018, is one of 222 in phase 1/2, and was the 1,064th registered.
3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →276 of the 1,780 studies in Ovarian Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Michael J. Goodheart · Sites in United States
Ages 18–99 · Women only
Crescent Biopharma, Inc. · Sites in United States
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, China, Israel and 2 more countries
Ages 18+ · Women only
Weill Medical College of Cornell University · Sites in United States
Ages 35+ · Women only
University of Alabama at Birmingham · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 602 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,780 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 770 · Phase 2 718 · Phase 3 114 · Phase 4 8
First in 1980; this study’s year is marked. 76 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 54 across 2,556 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 47 across the 1,499 interventional studies, 176 across the 195 observational. Of the 1,212 that completed or were terminated, 445 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
714 of 1,780 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Michael McHale as lead sponsor.
Michael McHale has 1 study filed under Ovarian Neoplasms — fewer than ten, so there is no comparison to draw.
160 of the studies in Ovarian Neoplasms with a site in United States that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT05281471Phase 3Genelux CorporationEfficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | 2026-12 |
| NCT04498117Phase 3CanariaBio Inc.Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | 2026-12-26 |
| NCT05059522Phase 3PfizerContinued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | 2026-12-31 |
| NCT04095364Phase 3NRG OncologyLetrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | 2027-02-01 |
Add all 160 to your calendar (.ics) → With an account.
Among the 1,780 studies in Ovarian Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to investigate the combination VS-6063, carboplatin, and paclitaxel. in the treatment of patients with ovarian cancer.
The purpose of the study is to investigate the combination VS-6063, carboplatin, and paclitaxel. in the treatment of patients with ovarian cancer. The study will evaluate whether this regimen is safe. The study will also evaluate whether the regimen can reduce the amount of cancerous cells in your body. If you agree, you will be treated with VS-6063 by mouth, as well as carboplatin and paclitaxel infusions. Carboplatin and paclitaxel are approved by the FDA for the treatment of ovarian cancer. VS-6063 is considered experimental because it is not approved by the FDA for the treatment of cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must have adequate:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Defactinib (VS-6063) (200 mg) + Carboplatin/Paclitaxel
Drug: VS-6063 · Drug: Paclitaxel · Drug: Carboplatin
Defactinib (VS-6063) (400 mg) + Carboplatin/Paclitaxel
Drug: VS-6063 · Drug: Paclitaxel · Drug: Carboplatin
Phase 1: * First 3 patient cohort: VS-6063 200 mg PO twice daily * IF TOLERATED, Second 3 patient cohort: VS-6063 400 mg PO twice daily, Phase 2: VS-6063 400 mg PO twice daily of a 28 day cycle until disease progression or unacceptable toxicity.
Also known as: defactinib
Phase 1: * First 3 patient cohort: paclitaxel 80 mg/m2 infused IV continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle. * IF TOLERATED, Second 3 patient cohort: paclitaxel 80 mg/m2 infused IV continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle. Phase 2: Paclitaxel 80 mg/m2 infused continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle until disease progression or unacceptable toxicity.
Also known as: Taxol
Phase 1: * First 3 patient cohort: carboplatin (AUC of 5 mg/mL/min) IV infused continuously over 1 hour on day 1 of a 28 day cycle. * IF TOLERATED, Second 3 patient cohort: carboplatin (AUC of 5 mg/mL/min) IV infused continuously over 1 hour on day 1 of a 28 day cycle. Phase 2: carboplatin (AUC of 5 mg/mL/min) infused continuously over 1 hour on day 1 of a 28 day cycle until disease progression or unacceptable toxicity.
Also known as: Paraplatin
Dose-Limiting Toxicity
Safety and tolerability of VS-6063 plus paclitaxel and carboplatin chemotherapy (Measured Via Adverse Events)
Time frame: 28 days
Objective Response Rate (ORR)
Time frame: 4 years
To Assess the Toxicity and Adverse Event Profile of VS-6063 Plus Paclitaxel and Carboplatin Chemotherapy (Measured Via Adverse Events)
Time frame: 4 years
To Describe Health-related Quality-of-life (QoL) Outcomes of Patients Receiving VS-6063 Plus Paclitaxel and Carboplatin Chemotherapy. (Measured Via Questionnaire)
Time frame: 4 years
Progression Free Survival (PFS)
Time frame: 4 years
Overall Survival (OS)
Time frame: 4 years
| Milestone | Defactinib (VS-6063) (200 mg) + Carboplatin/Paclitaxel | Defactinib (VS-6063) (400 mg) + Carboplatin/Paclitaxel |
|---|---|---|
| Started | 6 | 2 |
| Completed | 4 | 2 |
| Not completed | 2 | 0 |
| Withdrew: Screen failure | 2 | 0 |
Safety and tolerability of VS-6063 plus paclitaxel and carboplatin chemotherapy (Measured Via Adverse Events)
| Participants | Defactinib (VS-6063) (200 mg) + Carboplatin/Paclitaxel | Defactinib (VS-6063) (400 mg) + Carboplatin/Paclitaxel |
|---|---|---|
| Dose-Limiting Toxicity | 1 | 1 |
| Participants | Defactinib (VS-6063) + Carboplatin/Paclitaxel |
|---|---|
| Objective Response Rate (ORR) | 0 |
| Participants | Defactinib (VS-6063) +Carboplatin/Paclitaxel |
|---|---|
| To Assess the Toxicity and Adverse Event Profile of VS-6063 Plus Paclitaxel and Carboplatin Chemotherapy (Measured Via Adverse Events) | 0 |
| Participants | Defactinib (VS-6063) +Carboplatin/Paclitaxel |
|---|---|
| To Describe Health-related Quality-of-life (QoL) Outcomes of Patients Receiving VS-6063 Plus Paclitaxel and Carboplatin Chemotherapy. (Measured Via Questionnaire) | 0 |
| Participants | Defactinib (VS-6063) +Carboplatin/Paclitaxel |
|---|---|
| Progression Free Survival (PFS) | 0 |
| Participants | Defactinib (VS-6063) +Carboplatin/Paclitaxel |
|---|---|
| Overall Survival (OS) | 0 |
Collected over 22 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Defactinib (VS-6063) (200 mg) + Carboplatin/Paclitaxel | 0/4 (0%) | 2/4 (50%) | 3/4 (75%) |
| Defactinib (VS-6063) (400 mg) + Carboplatin/Paclitaxel | 0/2 (0%) | 1/2 (50%) | 1/2 (50%) |
| Event | Defactinib (VS-6063) (200 mg) + Carboplatin/Paclitaxel | Defactinib (VS-6063) (400 mg) + Carboplatin/Paclitaxel |
|---|---|---|
| Colonic ObstructionGastrointestinal disorders | 1/4 | 1/2 |
| Elevated White Blood Cell CountBlood and lymphatic system disorders | 1/4 | 0/2 |
| Event | Defactinib (VS-6063) (200 mg) + Carboplatin/Paclitaxel | Defactinib (VS-6063) (400 mg) + Carboplatin/Paclitaxel |
|---|---|---|
| Neutrophil count decreasedBlood and lymphatic system disorders | 3/4 | 0/2 |
| AnemiaBlood and lymphatic system disorders | 1/4 | 1/2 |
| FatigueGeneral disorders | 1/4 | 0/2 |
| White blood cell decreasedBlood and lymphatic system disorders | 1/4 | 0/2 |
| Age, Continuous(years) | Defactinib (VS-6063) (200 mg) + Carboplatin/Paclitaxel | Defactinib (VS-6063) (400 mg) + Carboplatin/Paclitaxel | Total |
|---|---|---|---|
| Median | 58.5 (41 to 66) | 60.5 (56 to 65) | 60 (41 to 66) |
| Sex: Female, Male(Participants) | Defactinib (VS-6063) (200 mg) + Carboplatin/Paclitaxel | Defactinib (VS-6063) (400 mg) + Carboplatin/Paclitaxel | Total |
|---|---|---|---|
| Female | 4 | 2 | 6 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Defactinib (VS-6063) (200 mg) + Carboplatin/Paclitaxel | Defactinib (VS-6063) (400 mg) + Carboplatin/Paclitaxel | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 3 |
| Not Hispanic or Latino | 2 | 1 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Defactinib (VS-6063) (200 mg) + Carboplatin/Paclitaxel | Defactinib (VS-6063) (400 mg) + Carboplatin/Paclitaxel | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 3 | 2 | 5 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| recurrent or persistent platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal(Participants) | Defactinib (VS-6063) (200 mg) + Carboplatin/Paclitaxel | Defactinib (VS-6063) (400 mg) + Carboplatin/Paclitaxel | Total |
|---|---|---|---|
| Count of participants | 4 | 2 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2018 to primary completion in Jul 2023, 65 months.
Results were first posted in Jul 2026, 3 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.